Cysteine Peptide-Enabled Antibody Functionalization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for enhancing the therapeutic efficacy of monoclonal antibodies are limited by available chemistries and require extensive protein engineering, and there is a need to functionalize antibodies through covalent bonds.
Innovation Solution
A covalent complex is provided, comprising an antigen binding domain with a non-CDR peptide binding region and a peptide compound covalently bound to the antigen binding domain through a disulfide linkage.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing methods are used to enhance therapeutic efficacy of monoclonal antibodies, then therapeutic efficacy is improved, but extensive protein engineering is required
Solution Approach 1:
The patent introduces a peptide intermediary that contains a cysteine residue capable of forming disulfide bonds with the antibody. This peptide acts as a mediator between the antibody and the therapeutic payload, enabling covalent attachment without requiring extensive modification of the antibody's protein structure. The peptide intermediary simplifies the engineering process while maintaining therapeutic efficacy.
Solution Approach 2:
The patent modifies the chemical parameters of the antibody by introducing specific cysteine residues at defined positions (such as Kabat position 102, 142, or 143 of the VL region, or Kabat position 208 or 158 of the VH region). This controlled parameter change allows for site-specific covalent bonding while avoiding the need for extensive protein engineering throughout the antibody structure.
2Adaptability or versatility
If covalent functionalization of antibodies is achieved through existing chemistries, then functionalization is enabled, but available chemistries are limited
Solution Approach 1:
The patent employs a peptide intermediary as a chemical bridge that overcomes the limitations of available antibody chemistries. The peptide contains a cysteine residue that provides a reliable disulfide bonding interface, expanding the range of feasible chemistries without requiring complex or unavailable chemical reactions on the antibody itself.
Solution Approach 2:
The patent changes the chemical state of the antibody by introducing free cysteine residues at specific positions, which alters the reactivity parameters of the antibody. This enables disulfide-based covalent functionalization, providing a versatile chemical platform that overcomes the limitations of existing antibody chemistries.
3Reliability
If site-specific cysteine residues are introduced for disulfide bonding, then covalent attachment is enabled, but antibody structure is modified
Solution Approach 1:
The patent applies local quality by introducing cysteine residues at specific, localized positions on the antibody surface (such as Kabat position 102, 142, or 143 of the VL region, or Kabat position 208 or 158 of the VH region). This localized modification enables covalent bonding capability at specific sites while leaving the rest of the antibody structure unchanged and stable.
Solution Approach 2:
The patent uses a peptide intermediary that can be easily synthesized and attached to the antibody. This peptide acts as a temporary, disposable element that facilitates covalent bonding but does not require permanent, complex structural changes to the antibody. The peptide can be designed and modified independently, simplifying the overall system.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The described approach allows for the efficient functionalization of antibodies through covalent bonds, enhancing their therapeutic efficacy without the need for extensive protein engineering.
Implementation Method 1
a peptide compound including a thiol side chain amino acid covalently bound to the antigen binding domain through a disulfide linkage between the first cysteine and the thiol side chain amino acid
Data Source
AI summary
Provided herein are functionalized monoclonal antibodies (mAbs) including antibody fragments covalently linked to a peptide compound through a disulfide linkage. The disulfide linkage is between a cysteine in the Fab region of the antibody or fragment thereof and a thiol moiety of a side chain amino acid of the peptide compound. The covalently formed complexes including provided herein form highly stable and versatile drug delivery and diagnostic compositions.